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1. INTRODUCTION 
In 2000, Europe made a commitment to achieving the Millennium Development 
Goals (MDGs) and the European Union (EU) adopted its new development policy, 
based on poverty reduction. At the same time, the European Commission (EC) 
developed a comprehensive frameworki to accelerate action targeted at the three 
major poverty diseases – HIV/AIDS, malaria and tuberculosis (TB). The Programme 
for Action (PfA),ii developed as a framework for implementation, remains just as 
valid today. The status of the PfA is illustrated in the progress report 2004.iii 
Significant achievements have been made on impact, affordability and research and 
development through coherent action between the policy areas of development, trade 
and research. 
The EU needs to accelerate action and address issues where progress has been slow. 
While maintaining the overall goal of poverty reduction, the EU also needs to 
respond to an increasingly changing global arena and rise to new challenges. There is 
a growing awareness of the effect that HIV/AIDS can have on human security and 
human rights. The changing nature and rapid spread of HIV/AIDS and TB globally 
also warrant consideration. Sustaining policy coherence regarding HIV/AIDS, 
malaria and TB remains a major challenge. 
This Communication provides the policy framework for all EC external action on 
confronting the three diseases. The Communication has been prepared following 
stakeholder consultations with third countries, EU Member States, civil society, 
industry, the Global Fund to Fight AIDS, TB and Malaria (the Global Fund), UN 
agencies, the World Bank and others. A stakeholder consultation meeting was 
organised in Brussels on 14 September 2004.iv Due to the re-emerging epidemic in 
Europe and its neighbouring countries, the Commission has highlighted the need for 
immediate action through a separate Working Paper adopted by the Commission on 
8 September 2004. This proposes a set of concrete actions for the next eighteen 
months.v These actions and recommendations to partners were endorsed in the 
“Vilnius Declaration” adopted by participants in the Ministerial Conference “Europe 
and HIV/AIDS: New Challenges, New Opportunities” (Vilnius, 17 September 2004). 
2. CHALLENGES 
2.1. Epidemiological, geographical and demographical challenges 
Despite increased efforts and resources, the number of people affected, infected and 
dying from HIV/AIDS, malaria and TB continues to rise. More than 6 million people 
in the world die each year from the three diseases, and the effectiveness of treatment 
is threatened by the emergence of multi-drug resistant malaria and TB. HIV/AIDS 
and TB are spreading rapidly, including in (European Neighbourhood Policy) ENP 
partner countries (e.g. Russia); the number of people with the diseases in countries 
with large populations (e.g. China and India) is increasing. Malaria poses a large 
burden particularly on African countries. Sub-Saharan Africa continues to carry the 
largest burden of HIV/AIDS and is home to two-thirds (an estimated 25 million 
people) of HIV-infected people globally.vi 
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Particularly with regard to developing countries, poverty reduction remains the main 
framework in which to confront the three diseases, as the diseases are often a 
consequence and a cause of poverty. HIV/AIDS, malaria and TB have a negative 
impact on the social and economic fabric of communities. The critical interaction 
between human security issues and the wider Cairo agenda (including HIV/AIDS, 
and gender-based violence) is becoming increasingly obvious. This demands 
consideration of human security and human rights. The spread of the three diseases 
among refugees and people living in conflict situations remains a challenge. The 
HIV/AIDS pandemic continues to affect women disproportionately in terms of 
infection rate, impact and lack of access to prevention, treatment and care. 
Consideration of vulnerable children, including the 12 million AIDS orphans in 
Africa, remains a challenge. 
2.2. Challenges to maintain a comprehensive policy mix of prevention, treatment 
and care 
HIV/AIDS, malaria and TB can be prevented and treated, but more countries need to 
develop appropriate strategies with a comprehensive policy mix integrating proven 
prevention, care and treatment. Successful programmes contain a balanced response. 
Condom use, and harm reduction programmes including needle-exchange for 
injecting drug users, have to be promoted as methods of HIV/AIDS prevention. 
Many health systems are showing signs of weak infrastructures and overstretched 
human resources; given the growing care and treatment needs for HIV/AIDS, 
maintaining an adequate focus on prevention and care poses a challenge. Provision of 
treatment requires more predictable and long-term resources. Research into new 
interventions is needed to deal with changing forms of the diseases. Capacity 
building for research and health services is also an integral part of the strategy. 
2.3. Challenges in financing 
Resources allocated to HIV/AIDS have increased globally, primarily because of an 
increase from domestic budgets and the private contribution (see Annex 1, Table 2). 
There are scant global funding figures available on malaria and TB. 
Despite the increase, a considerable gap remains in terms of external resources to 
confront the three diseases (see Table 1). The international community will need to 
secure appropriate funding to match demand.UN estimates of the resources needed 
by region to confront HIV/AIDS over the next few years are given in Annex 1, Table 
3. However, this Communication does not have financial implications for the EC. 
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Table 1 – Estimated annual ODA and external resource gapvii 
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2.4. Challenges in governance at country and global levels 
Reaching the affected countries, the poorest people, and the disenfranchised of 
all societies remains a challenge. Populations already facing barriers to care (in 
particular women and the poor) have become increasingly marginalised. Many 
behaviours associated with increased risk of HIV/AIDS (e.g. men having sex with 
men, injecting drug use, commercial sex work) are often socially unaccepted; people 
living with HIV/AIDS and TB are often met with stigma and discrimination. This 
prevents open dialogue, and can lead to poor access and uptake of prevention 
methods, testing and treatment. Enabling youth, women and people affected by the 
diseases to have a stronger voice in planning, policy and implementation is crucial to 
address needs. 
Strong leadership within countries is essential, with political commitment behind 
effective policies and consequent mobilisation of resources. Particularly in many of 
the poorest countries with weak government structures and in ENP partner countries, 
the acknowledgement among political leaders of the need to address HIV/AIDS and 
TB is a challenge. 
The fact that the three diseases know no institutional or national boundaries is 
another challenge. Confronting them requires strong cooperation between all partners 
in society. Some countries have managed to establish cross-sectoral cooperation with 
concrete results. The Country Coordinating Mechanisms (CCMs) set up to access 
Global Fund support can play a strong role in catalysing cooperation between 
different partners, promoting harmonisation and facilitating implementation. 
Confronting the three diseases often requires a cross-border response, which is 
difficult where regional institutions are weak. 
Increasing the efforts of the private sector to supply resources and skills is a major 
challenge. The private sector has significant untapped potential to invest in 
developing countries. Increasing private sector efforts in the area of tiered prices on 
their products, and in their contribution to multilateral initiatives (e.g. the European 
and Developing Countries Clinical Trials Partnership (EDCTP) and the Global 
Fund), remains a challenge. 
 EN 6   EN 
The lack of vocal representation and the imbalance of power on global issues also 
represent a challenge in terms of global governance on health. Many countries do 
not have the voice, negotiation capacity or voting rights to design and implement 
global rules to their advantage (e.g. regarding research priorities and regulatory 
frameworks). The increase in the number and diversity of global initiatives and 
players in the HIV/AIDS, malaria and TB arena has further altered the global 
institutional structure, and poses opportunities and challenges in terms of 
harmonisation and coherence. The recent enlargement of the EU has brought the 
impact of HIV/AIDS and TB in ENP partner countries in Eastern Europe higher on 
the European agenda. 
3. EU VISION 
3.1. Vision for 2015 
The EC will continue to respond to the evolving nature of the three diseases and their 
geographic spread in developing countries and in ENP partner countries. The EC and 
the EU Member States have made international commitments and share a long-term 
vision towards confronting the three diseases and reaching the MDG target date of 
2015. Through its humanitarian aid, development, trade, health and external relations 
policies, the EU contributes to achieving the MDGs, including MDG 6 on 
“combating HIV/AIDS, malaria and other diseases”. 
All EU Member States endorsed the Programme of Action adopted in Cairo in 1994 
at the International Conference on Population and Development (ICPD). The Cairo 
agenda on sexual and reproductive health and rights (emphasising a voluntary, 
people-centred approach based on informed choice) is clearly reflected in EU 
policies and advocacy positions. The EC and the EU Member States were signatories 
to the Declaration and Platform for Action of the 1995 World Conference on Women 
in Beijing. The Platform stressed the need for action against world-wide obstacles to 
gender equality, and established gender mainstreaming as a main strategy.viii All EU 
Member States have ratified the UN Convention on the Rights of the Child. The 
commitment to human rights is also clear in the EC Development Policy 
Statement.ix The commitments to MDGs, Cairo, Beijing, human rights and human 
security are core pillars of the EU vision for confronting the three diseases. 
Increasing resources and coordinating efforts are also part of the EU vision. The 
0.7% of gross national income (GNI) remains a recognised target for EU Member 
States’ allocations to ODA. The EU is well on track to achieving commitments made 
in Monterrey (March 2002);x based on current trends, the EU will provide 0.42% of 
its collective GNI in ODA by 2006 (€38.5 billion).xi This means an increase of €10 
billion per year of EU ODA. The EC and the EU Member States are bound by the 
Treaty to operate in coordination and complementarity in the field of development 
cooperation, a commitment reaffirmed at the High-Level Forum on Harmonisation in 
Rome (2003). The principles of harmonisation across strategy, agency and 
monitoring plan are also reflected in the 3 Ones approach to HIV/AIDS.xii 
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3.2. Principles 
Several shared principles guide Europe’s cooperation with third countries. The EU 
closely adheres to the overall development goal of reducing poverty, achieving the 
MDGs and respecting rights. The principle of equity means that services need to 
reach those who are most in need. Ensuring countrywide ownership remains a 
guiding principle. Countries remain the key decision-makers responsible for 
formulating their strategic priorities and national frameworks. Governments are 
accountable to their electorates for their choices and for implementation. Good 
governance, with the ability to ensure transparent processes and maintain the rule of 
law, is an integral part of country action. Governance beyond state institutions is also 
important to ensure demand-driven responses with broad participation, including 
civil society and the private sector. Working with third countries also requires the 
scaling-up of actions, and increasing sustainable resources, with complementary 
investment in enhanced capacity. 
4. EC ADDED VALUE AND EC ACTIONS 
4.1. EC added value 
As seen from the progress report and consultations, the EC has several attributes of 
comparative advantage for action on the three diseases. The majority of EC financial 
support instruments are, and will remain, at country level. The EC, together with the 
EU Member States, will also continue to address key issues at global level. 
The EC has successfully cooperated across policy areas of development, 
humanitarian aid, trade, and research towards coherent external action. Activities in 
different policy areas can reinforce each other and produce greater synergy. This is 
the added value of the EC, and goes beyond what EU Member States can do 
individually (as has been evident from implementation of the PfA, and advocacy for 
ICPD and the Doha Declaration on TRIPs and public health). The EC also has added 
value in its ability to convene, represent and defend a common European position 
globally, thus improving coherence in global governance. Coherence between EU 
Member States and the EC will become increasingly important. Human security, 
including the links with HIV/AIDS, is an important consideration in the evolving 
field of a Common Foreign and Security Policy. 
At country level, EC added value includes its working presence in many 
countries,xiii including several neighbouring countries and those where some EU 
Member States are absent, as well as the ability to provide support for recurrent 
costs, e.g. salaries of health staff and commodity purchasing – a major component of 
health expenditure. 
A final aspect of added value is the flexibility in the current EC thematic budget 
lines, which allow for the financing of innovative actions both at country and at 
global level. This has allowed for support to the Global Fund, to the International 
AIDS Vaccine Initiative (IAVI), to the International Partnership for Microbicides 
(IPM), and to the EDCTP sites for clinical trials in disease-endemic countries. Such 
flexibility should be retained in the new financial instruments for EC external action 
(2007-2013). 
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4.2. EC action at country level 
The geographic spread of the diseases requires a focus beyond developing countries. 
In particular, multi-drug resistant TB and HIV/AIDS are spreading fast in ENP 
partner countries. The EC is able to provide a policy mix of country support through 
various financial instruments and for different social services; a country can ask for a 
different range of inputs depending on its needs. The poorest countries need the 
most financial resources, resources related to political commitment, technical 
capacity building, and policy dialogue, and close partnership. Middle-income 
countries, including the new neighbouring countries in Eastern Europe mostly 
need support in their policy dialogue and political commitment, and in technical 
capacity building. In areas of difficult partnershipsxiv (commonly characterised by 
human rights violations, political repression, high levels of corruption, or violent 
conflict), the EC will remain engaged and adopt specific strategies such as LRRD 
and working pragmatically with committed organisations inside and outside of 
government. 
4.2.1. Increase capacities 
The EC will actively focus on enhancing human resource capacity in national 
development plans, such as the Country Strategy Papers (CSPs), Partnership and 
Cooperation Agreements, and Poverty Reduction Strategy Papers. This will 
strengthen social services, including health and education. Improving human 
resource capacity includes accelerated action on staff training, career development, 
appropriate remuneration and retention of staff, and responsive management. These 
actions will address some of the key motivational problems faced by health staff, and 
might therefore dent the drastic brain drain of staff from rural to urban, from public 
to private, and from developing to developed countries. The EC recommends 
countries and donors to agree on a financing model where disease-specific initiatives 
contribute a defined proportion of their funds to health care delivery, including the 
development of human resources. The EC could also explore a European code of 
conduct for recruiting staff from third countries; or for organisations employing 
national staff to train counterpart staff within the government structure. These 
proposals should be further developed in the High-Level Forum on Health. 
The EC encourages capacity enhancement of broad-based national and regional 
(e.g. NEPAD) bodies focusing on the three diseases with participation of 
government and non-government stakeholders at country level (e.g. CCMs where 
they are present). EC delegations will be more actively involved in capacity building 
and establish complementary partnerships with EU Member State representatives to 
provide technical assistance. 
In its policy dialogue, the EC will encourage countries to develop strategies which 
recognise the value of investing in people and in social services. A comprehensive 
policy mix, including prevention, treatment and care, is necessary. An appropriate 
mix depends on the nature of the disease, capacities and resources available, and best 
practice. For HIV/AIDS, evidence shows that condom use and open discussion of 
sexual activity – rather than abstinence – are the most effective tools for preventing 
sexual transmission. A recent study on India illustratedxv that increasing the current 
rate of condom use during high-risk contacts from 50% to 70% would be enough to 
change the direction of the epidemic in India. 
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The EC will strengthen surveillance and monitoring capacity of health outcomes 
through continued support of the Health Metrics Networkxvi and UNAIDS. The EC 
will emphasise the tracking of health data beyond the currently used ten MDG-linked 
core indicators. It will become increasingly important to demonstrate that 
macroeconomic support allows countries to address priorities in social services. The 
EC will work with EU Member States to assess whether macroeconomic support 
allows for increased resource flows to social services, and whether this translates into 
improved health outcomes. 
The EC will focus on the critical interaction between human security and the Cairo 
agenda in discussions with personnel participating in conflict-resolution, peace-
keeping and post-conflict operations. The full Cairo agenda – including HIV/AIDS, 
gender-based violence and provision of contraceptives – needs to be an integral part 
of the analysis of conflicts, their causes, effects and resolution. 
The EC will support local production capacity, e.g. for raw materials and 
formulations of artemisinin-based combination therapies (ACT) and other new 
antimalarials, insecticide-treated bednets, condoms, and generic production of 
essential drugs – including fixed-dose combinations (FDCs) for TB and HIV/AIDS. 
Local production can promote competition and make pharmaceutical products more 
affordable. It is important to encourage technology transfer to ensure that locally 
produced pharmaceutical products meet internationally agreed standards. The EC 
will pursue this through cooperation with the European Investment Bank. 
The EC will continue to strengthen developing countries’ capacities to conduct 
research, particularly in clinical trials. Synergies between capacity building for 
research and training of staff for healthcare services should be explored, with the 
active involvement of partner countries. The EDCTP should play an integrating role 
by contributing to both national and regional human resource plans for clinical 
research. 
4.2.2. Increased and sustainable resources 
Countries need increased long-term, sustainable resources, from a variety of 
sources, to confront the three diseases. Countries need to invest an appropriate 
portion of their budget in social services to achieve improved health outcomes. The 
WHO-World Bank Commission on Macroeconomics and Health recommends an 
annual budget allocation to health of at least US$40 per capita. The current annual 
gap in reaching this recommendation is over €120 billion. Private investment in third 
countries and official development assistance (ODA) are needed.xvii The EU should 
continue to adhere to commitments made in Monterrey on raising ODA. The 
capacity of countries to absorb increased resources should be addressed, and 
medium-term expenditure frameworks developed that encourage flexibility in 
investment ceilings. 
The EC will increase funding support to confronting the three diseases through 
innovative action. The Global Fund has proven to be a comparatively fast way of 
channelling EC funds into confronting the three diseases at country level and has 
already shown key results. According to Global Fund projections based on demand 
from the countries concerned a tripling of the annual average level of donor 
contributions is needed, from the current US$1 billion to US$3 billion by 2008.xviii 
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The need for a substantial EU contribution, in the region of US$ 1 billion annually, 
has already been discussed at the EU Thessaloniki summit. The 2005 high-level 
replenishment conference of the Global Fund is an opportunity for all donors to 
increase their contributions. If this conference re-confirms the projections made, the 
EU will be expected to contribute to increased funding needs. Contributions will be 
expected from both the EC and from EU Member States, based on a model for fair 
European burden sharing. 
4.3. EC action at global level 
4.3.1. Affordable and safe pharmaceutical products 
The EC will continue to advocate a reduction in the price of pharmaceutical 
products. The EC will continue to encourage tiered pricing through, inter alia, the 
use of the anti-trade diversion Regulation on a broader range of products (including 
anti-retroviral second-line treatments, FDCs, paediatric formulationsxix and other 
products such as ACTs). The EC encourages competition between the R&D based 
industry and generic producers and public tendering based on fair and transparent 
procurement rules to reduce prices. 
The EC will also encourage countries to publish in a transparent manner prices of 
commodities purchased, whether through the Global Fund (where prices paid are 
already made public), or through other mechanisms. This will become standard 
practice for EC-funded programmes purchasing pharmaceutical products. 
The EC emphasises adherence to the Doha Declaration on TRIPs and public 
health (2001), and to the August 2003 Decision,xx including assurance that the 
Declaration is not undermined either in formal amendments of the TRIPs Agreement, 
through bilateral negotiations, or through national legislation. The EC encourages 
developing countries to make use of TRIPs flexibility and exemptions, including 
compulsory licensing while stressing the importance of an adequate intellectual 
property regime. 
The EC will provide technical assistance to improve countries’ capacities in 
pharmaceutical policies, including through continued and strengthened partnership 
with WHO on prequalification. The EC will continue to emphasise the need for safe 
pharmaceutical products. The EC Enforcement Strategy Paper (June 2004) contains 
guidelines for EC action on the enforcement of intellectual property rights in third 
countries, which will be considered along with public health needs. 
4.3.2. Regulatory aspects 
The EC will support the enhanced capacity of third countries to perform regulatory 
tasks, including the approval of clinical trials and the granting of market 
authorisation. Regulatory challenges for new vaccines, microbicides and diagnostics 
need to be addressed.xxi The European Medicines Agency (EMEA) and national 
regulatory authorities in the EU, could support – in coordination with WHO – 
capacity building for regulatory bodies through partnerships, scientific/technical 
assistance or financial support. This should focus on establishing regional centres of 
regulatory expertise in, for example, Brazil, South Africa and Thailand. Regulatory 
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procedures should not be used as trade obstacles, which could make pharmaceutical 
products more expensive. 
Assistance provided by the EMEA will build on the recent revision of the EU 
pharmaceutical legislation, enabling the EMEA to give a scientific opinion for the 
evaluation of medicines to be marketed exclusively outside the Communityxxii. This 
procedure, open to both R&D and generic manufacturers, should enable the 
Community to provide scientific support to developing countries, thereby facilitating 
rapid access to medicinal products which meet their own public health needs.xxiii 
4.3.3. New tools and interventions 
The EC will continue to focus on developing new, effective, safe and affordable 
tools and interventions, by investing in research and development. New effective 
vaccines would be the most powerful and cost-efficient tool to confront the three 
diseases, but a comprehensive research approach will remain important, in the 
foreseeable future.xxiv Research in new interventions should focus on vaccines for the 
three diseases, microbicides to prevent HIV/AIDS transmission,xxv new diagnostics 
and treatments for TB in the context of resistance and low compliance, and improved 
prevention and treatment for malaria. Special attention should be given to FDCs, 
paediatric formulations, and treatment regimens for multiple concurrent infections. 
The EC will continue to support EDCTP in order to increase the number of new 
candidate vaccines and other products entering clinical trials. The EC will encourage 
Member States and industry to invest in and make use of the EDCTP programme. 
The EDCTP will ensure coherence and synergy between clinical trials carried out by 
itself and by other organisations. 
The results of extensive monitoring in the relevant social and economic context 
should be used to improve the impact of existing interventions and diagnostic tools. 
Epidemiology and applied research will therefore be an integrated part of the 
research agenda. 
Following stakeholder consultations, the EC will establish incentives to harness the 
capacity of private industry, including small and medium-sized biotech enterprises, 
in the development of new tools targeting the three diseases. Incentives could 
include: the extension of patent rights and/or market exclusivity, including through 
the relationship which might be established between different products, simplified 
and faster regulatory procedures, venture capital, low cost loans, tax credits and 
guaranteed markets. 
4.3.4. Strengthened partnerships and a strong European voice 
The EC will continue to cooperate closely with EU Member States – on technical 
assistance, strengthening regulatory capacity in developing countries, and promoting 
and coordinating research. The EC will also continue to seek common European 
positions in multilateral institutions and mechanisms, including the Global Fund. 
The EC will continue and strengthen policy dialogue and funding to multilateral 
UN organisations: the strategic partnership with WHO (on pharmaceutical policy, 
regulatory issues, and health monitoring), and the strong partnership with UNAIDS 
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(regarding the 3 Ones) and UNFPA (for the Cairo agenda). This should be seen as 
part of an EC response to the challenges posed in terms of global governance for 
health. 
The EC will continue to support demand-driven country programmes through 
the Global Fund (see Annex 2 for more details). 
The EC will continue to support a needs-driven global research agenda by supporting 
the EDCTP and by partnering with other international research initiatives, such as 
IAVI, IPM, GAVI, and the Global HIV Vaccine Enterprise (endorsed by G8). 
The EC will continue to present a strong voice advocating common European 
values at fora following Cairo and Doha, with the ultimate goal of achieving the 
MDGs by 2015. 
5. EC TOOLS 
Coherence remains an integral component of the EC policy framework. Coherence 
and coordination need to be reflected in the EC institutional set-up, perhaps with a 
clearly defined lead service, to ensure EC-wide accountability. Measures will also be 
put in place to ensure coordination between EC services, including delegations, 
responsible for various parts of the programming cycle. These proposals will be 
developed in more detail in the Programme for Action. 
The new EC financial perspectives (2007-2013) offer increased opportunities and 
scope for leadership to confront global challenges, including the three diseases. The 
new financial instruments benefit the poorest countries, while also supporting the EU 
neighbourhood. Six instruments are proposed, three supporting EU external policies 
(pre-accession, neighbourhood and development), and three thematic instruments to 
respond to political, humanitarian and financial crisis situations (See Annex 3, Table 
4).xxvi While this Communication does not have financial implications, a Programme 
for Action will be presented at a later stage specifying actions in various regions and 
proposing resource allocations. 
The EC Round-table discussion in 2000 established a momentum for action between 
different stakeholders. The EC will continue to amplify this momentum, and 
establish a Stakeholder Forum to ensure continued consultation, including people 
living with HIV/AIDS, malaria or TB, on how to confront the three diseases and on 
instruments and financing needed. 
6. CONCLUSION 
The Policy framework (2000) and the Programme for Action adopted in 2001 
achieved significant results in confronting the three diseases within the context of 
poverty reduction. Much of this was due to synergy between EC research, trade and 
development policies. Based on these experiences and following consultation with 
stakeholders, including developing countries and ENP partner countries in Vilnius, a 
coherent policy framework for all EC external action to confront the three diseases is 
presented in this Communication. The Communication will be brought before the 
Council under the Dutch Presidency, and submitted to the European Parliament. 
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Based on this comprehensive policy framework, new strategies and action 
programmes will be developed. These will refer to the use of specific instruments 
and resources, and will propose further coordination with EU Member States. The 
Commission Working Document prepared for Vilnius already outlines specific 
actions for ENP partner countries in Eastern Europe. 
Europe has a leadership role to play in confronting HIV/AIDS, malaria and TB 
globally. The current EU Presidency (the Netherlands), and future Presidencies 
(Luxembourg, the UK, Austria and Finland) have given priority to confronting the 
three diseases and adhering to the full Cairo agenda. Communicable diseases remain 
prominent on the global agenda – in UN fora and the G8. Europe’s contribution to 
turning the tide of the HIV/AIDS pandemic, and confronting malaria and TB, will 
help to achieve the ultimate aim of the MDGs – reducing poverty for millions of 
people worldwide. 
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Annex 1: Resources spent, and resources needed, for HIV/AIDS 
Table 2: Resources invested in HIV/AIDS, 1996-2003xxvii 
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Table 3: Projected Annual HIV/AIDS financing needs (in US$ million) by 
region (2004-2007)xxviii 
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Annex 2: The Global Fund to Fight AIDS, TB and Malaria and the EU’s role 
The Global Fund was established to generate additional public and private resources 
to confront the three diseases. It departs from traditional forms of multilateral 
governance because non-state actors share decision-making powers and financing 
responsibilities with national governments. This reflects the political implausibility 
of raising much-needed funds through the UN, while still remaining reliant on the 
infrastructure and support of UN agencies, funds and programmes. For example, 
WHO and UNAIDS are providing technical aid and administrative support and 
building capacities. The Global Fund was also established to be a model of 
performance-based funding. While not a purchasing institution, the funding provided 
to support demand-based proposals made by countries, and the transparency in 
purchasing, can help to reduce prices of pharmaceutical products and commodities. 
The demand generated could also have a medium-term leverage effect on research 
into new tools to confront the three diseases. 
A forecast of the Global Fund operations and the business modelxxix illustrates that, if 
the current business model is pursued, the Global Fund will reach an annual value of 
approvals, commitments and disbursements of US$3 billion from 2008 onwards. 
This forecast predicts a considerable increase in both the demand for resources and 
the workload compared to the current levels. Although disbursements have been 
slow initially, they would speed up over the next three years to meet the level of 
approvals. 
The annual average level of donor contributions to the Global Fund would have to 
triple from its current US$1 billion to respond to the increase in resource demands. 
The 2005 high-level replenishment conference of the Global Fund is an opportunity 
for all donors to increase their contributions to the Fund. As tens of thousands of 
people begin receiving anti-retroviral treatment financed by the Global Fund, the 
issue of sustainable and predictable funding is even more important. Countries 
should gradually move towards self-sustaining financial systems. However, faced 
with severe resource constraints in the poorest countries, the global community will 
need to continue its support for many years to come. 
Other future challenges to the Global Fund for the EC/EU to take a position on in the 
Board meetings are the difficulty of some poor countries to effectively use large 
sums of money, especially with the significant brain drain in developing countries, 
which depletes human resources, particularly in the health services most needed. It 
has also been discussed whether the disease-specific approach committing global 
finance primarily to the three diseases, instead of health services, is, in general, 
beneficial. The Global Fund programmes have so far been successful in delivering 
the demand at country level. Some countries have even exceeded performance 
targets and disbursements have been made faster than expected. In a recent 
performance review made by the Global Fund, the 25 grants that had passed one year 
of operations were performing above the targets set and in comparison with other 
donors. On average for all grants reviewed, 70 percent of the expected disbursements 
had been made, and the disbursement rate was climbing. Some of the programmes 
had achieved spectacular results. For instance, in the Global Fund TB programmes in 
China, Ghana, Indonesia, Mongolia, Panama and Sri Lanka, performance targets 
were exceeded by 32%.xxx 
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Developing countries have expressed positive views on the Global Fund’s 
performance and have, in particular, underlined ownership based on the national 
development of programmes and global representation at Board level; the 
flexibilities offered by Global Fund financing, especially with regard to recurrent 
costs, which are rarely permitted under the guidelines of most other aid agencies 
(with the exception of the EC); and the openness and transparency in transactions 
(e.g. the Global Fund’s activities are accessible on its website, including the results 
of negotiations of pharmaceutical product pricing). 
If sufficient resources are provided to meet the increase in demand, then the current 
business model must be adapted to make the operations more effective and reduce 
transaction costs. Key suggestions to streamline Global Fund procedures include: 
• The Global Fund could adopt a differentiated approach based on a risk analysis, 
taking into account contextual considerations and past performance of grant 
receivers. 
• The Global Fund could establish a public and a private funding channel in a 
country with an approved proposal. The principal recipient for the public channel 
would be likely to be the Ministry of Health or the Ministry of Finance, while the 
private channel could be NGOs and take on a country-appropriate form. 
• Existing mechanisms such as the country-specific accreditation scheme (planned 
by the Health Metrics Network) for monitoring and evaluation systems could also 
be used as a standard for assessments, rather than using a parallel Global Fund 
assessment system. 
• The Global Fund Secretariat could play a more active role in identifying needs for 
technical assistance, and garner support from donor agencies and other partners 
present in the country to improve the provision of such assistance. 
Any changes in the Global Fund business model must be based on the ability to serve 
the Global Fund recipients, both those who will directly receive and use funding and 
the people and communities living with, affected by and at risk from HIV/AIDS, TB 
and malaria. The performance of the Global Fund programmes is measured by their 
ability to reach the poorest and most vulnerable. 
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Annex 3: New EC financial instruments (as proposed by the EC, September 2004) 
Table 4 should be used for initial reflection on the potential use of EC financial instruments for external action to confront the three diseases. Specific 
proposals will be presented in a Programme for Action. 
Table 4: Overview of the proposed new EC financial instruments and their potential to be used in confronting HIV/AIDS, malaria and TB 
Instruments 2007-13 (total 
amounts) 
Beneficiary countries What policy mix in regard to 
confronting three diseases? 
Channels of cooperation/financing 
Development Cooperation and 
Economic Cooperation 
Instrument (DCECI) 
(€41 088 million) 
All non-Member States (incl. 
their overseas territories) not 
covered by IPA and ENPI 
Long-term development 
assistance. Focus on Treaty 
objectives (mainly Art. 177), 
international engagements of the 
EC incl. MDG 
Coherence of policies; coordination with MS; coordination 
with international donors; sectoral and budget support; 
respect for HR and fundamental freedoms. Geographical as 
well as thematic and horizontal multi-annual programming 
and subsequent annual action programmes. 
European Neighbourhood and 
Partnership Instrument (ENPI) 
(€13 856 million) 
Algeria, Armenia, Azerbaijan, 
Belarus, Egypt, Georgia, Israel, 
Jordan, Lebanon, Libya, 
Moldova, Morocco, Palestinian 
Auth., Russian Federation, Syria, 
Tunisia, Ukraine 
Institution building, political 
cooperation “Supporting policies 
to fight poverty and promote 
social development, health, 
education and training, 
employment and social 
protection”. 
CSPs give margin for inclusion of disease-related financing. 
Thematic programmes “to address in a visible and 
recognisable way global challenges of particular importance” 
for all partner countries. MS can be associated for joint 
projects. 
Instrument for Pre-Accession 
Assistance (IPA) 
(€13 271 million) 
Croatia, Turkey, Western Balkans Institution building, human 
resources development, cross-
border cooperation, No specific 
provision for health systems. 
Financing through instruments similar to the structural funds 
and PHARE/ISPA/SAPARD structure. Association 
agreements. 
Stability instrument 
(€4 258 million) 
All third countries (except 
overseas territories of EU) 
Rapid response to crises; most 
activities DAC eligible; “major 
unexpected threats to public 
health” 
Complementary to the other instruments. 
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